Rekha Rakesh Jhunjhunwala-Backed Small-cap Company Signs LOI with UCSF and Tiller Therapeutics – Complete Details Inside!

The company’s shares have delivered an impressive return of over 15 per cent in the past 1 month.

Sun Pharma Advanced Research Company Ltd has announced the signing of a binding Letter of Intent (LOI) with the University of California, San Francisco (UCSF) and Tiller Therapeutics Inc. (Tiller) for licensing its pre-clinical oncology asset and associated intellectual property (IP). The asset, developed over a three-year collaboration between SPARC and UCSF, will now be advanced by Tiller for further development and commercialization.

Under the LOI terms, SPARC will secure a 55 per cent equity stake in Tiller Therapeutics. This stake will vest in two phases: 45 percent upon execution of the license agreement and the remaining 10 per cent upon achieving certain milestones or within six months of the agreement’s execution. Detailed terms will be formalized in the license agreement.

Anil Raghavan, CEO of SPARC, expressed his enthusiasm, stating, “We are excited about the opportunity to partner with Tiller to advance the potential treatment of solid tumors affecting millions each year, with no current cure.”

Rekha Rakesh Jhunjhunwala owns around 1.94 per cent stake in the company as per the recent quarterly update.

Sun Pharma Advanced Research Company Ltd (SPARC) is a pharmaceutical innovation company dedicated to improving global healthcare standards through advanced therapeutics and drug delivery systems.

Sun Pharma Advanced Research Company Ltd shares are trading at around Rs 227.60 per share. The company’s current market capitalization stands at Rs 7,386 crore. The company’s stocks have delivered an impressive return of over 15 per cent in just 1 month.

Investors must keep this Rekha Rakesh Jhunjhunwala-backed Small-Cap stock on their radar.

Disclaimer: The article is for informational purposes only and not investment advice.